These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 11376182

  • 1. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.
    Rudick RA, Cutter G, Baier M, Fisher E, Dougherty D, Weinstock-Guttman B, Mass MK, Miller D, Simonian NA.
    Neurology; 2001 May 22; 56(10):1324-30. PubMed ID: 11376182
    [Abstract] [Full Text] [Related]

  • 2. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients.
    Fisher E, Rudick RA, Cutter G, Baier M, Miller D, Weinstock-Guttman B, Mass MK, Dougherty DS, Simonian NA.
    Mult Scler; 2000 Dec 22; 6(6):373-7. PubMed ID: 11212131
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW.
    Mult Scler; 2009 Aug 22; 15(8):984-97. PubMed ID: 19667023
    [Abstract] [Full Text] [Related]

  • 5. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.
    Baier ML, Cutter GR, Rudick RA, Miller D, Cohen JA, Weinstock-Guttman B, Mass M, Balcer LJ.
    Neurology; 2005 Mar 22; 64(6):992-5. PubMed ID: 15781814
    [Abstract] [Full Text] [Related]

  • 6. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
    Mezei Z, Bereczki D, Csiba L, Csépány T.
    Ideggyogy Sz; 2006 Nov 20; 59(11-12):442-7. PubMed ID: 17203882
    [Abstract] [Full Text] [Related]

  • 7. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
    Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN, IMPACT Investigators.
    Neurology; 2002 Sep 10; 59(5):679-87. PubMed ID: 12221157
    [Abstract] [Full Text] [Related]

  • 8. Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis.
    Nourbakhsh B, Azevedo C, Maghzi AH, Spain R, Pelletier D, Waubant E.
    J Neurol Sci; 2016 Jul 15; 366():229-233. PubMed ID: 27288812
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials.
    Rudick RA, Cutter G, Reingold S.
    Mult Scler; 2002 Oct 15; 8(5):359-65. PubMed ID: 12356200
    [Abstract] [Full Text] [Related]

  • 12. Eight-year follow-up study of brain atrophy in patients with MS.
    Fisher E, Rudick RA, Simon JH, Cutter G, Baier M, Lee JC, Miller D, Weinstock-Guttman B, Mass MK, Dougherty DS, Simonian NA.
    Neurology; 2002 Nov 12; 59(9):1412-20. PubMed ID: 12427893
    [Abstract] [Full Text] [Related]

  • 13. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
    Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA, CARE-MS II Investigators.
    Neurology; 2016 Nov 08; 87(19):1985-1992. PubMed ID: 27733571
    [Abstract] [Full Text] [Related]

  • 14. Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis.
    Waldman AT, Chahin S, Lavery AM, Liu G, Banwell BL, Liu GT, Balcer LJ.
    Mult Scler Relat Disord; 2016 Nov 08; 10():73-78. PubMed ID: 27919503
    [Abstract] [Full Text] [Related]

  • 15. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
    Kragt JJ, Thompson AJ, Montalban X, Tintoré M, Río J, Polman CH, Uitdehaag BM.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1084-91. PubMed ID: 18184917
    [Abstract] [Full Text] [Related]

  • 16. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.
    Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M.
    Neurology; 2001 Oct 09; 57(7):1239-47. PubMed ID: 11591843
    [Abstract] [Full Text] [Related]

  • 17. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life.
    Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS.
    Arch Neurol; 2000 Sep 09; 57(9):1319-24. PubMed ID: 10987899
    [Abstract] [Full Text] [Related]

  • 18. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
    Burt RK, Balabanov R, Han X, Sharrack B, Morgan A, Quigley K, Yaung K, Helenowski IB, Jovanovic B, Spahovic D, Arnautovic I, Lee DC, Benefield BC, Futterer S, Oliveira MC, Burman J.
    JAMA; 2015 Jan 20; 313(3):275-84. PubMed ID: 25602998
    [Abstract] [Full Text] [Related]

  • 19. Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis.
    Miller DM, Rudick RA, Baier M, Cutter G, Doughtery DS, Weinstock-Guttman B, Mass MK, Fisher E, Simonian N.
    Mult Scler; 2003 Feb 20; 9(1):1-5. PubMed ID: 12617260
    [Abstract] [Full Text] [Related]

  • 20. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years.
    Turner B, Lin X, Calmon G, Roberts N, Blumhardt LD.
    Mult Scler; 2003 Feb 20; 9(1):21-7. PubMed ID: 12617263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.